Table 1

Baseline characteristics of patients with systemic sclerosis

TotalMedical interventionNo medical intervention
N=226N=191N=35
Sociodemographics
 Age, years, mean (SD)54 (14.5)54.5 (14.9)51.4 (11.5)
 Female, N (%)186 (82)157 (82)29 (83)
 Caucasian origin, N (%)151 (67)127 (67)24 (69)
 Smoking, current, N (%)32 (14)28 (15)4 (11)
 Education level, N (%)*
  Low89 (41)76 (41)13 (39)
  Medium78 (36)68 (36)10 (30)
  High53 (24)43 (23)10 (30)
Disease characteristics, N (%)
 DcSSc73 (32)62 (33)11 (31)
 mRSS, median (IQR)3 (1–6)4 (1–6)2 (2–6)
 Disease duration, years, median (IQR)4 (1–11)3 (1–11)4 (1–10)
 Onset of Raynaud's phenomenon, years, median (IQR)*12 (5–20)12 (5–20)10 (5–201)
 Onset of non-Raynaud's phenomenon, years, median (IQR)†6 (3–13)6 (2–13)6 (3–11)
 Digital ulcers62 (28)57 (30)5 (14)
 Telangiectasia133 (59)118 (62)15 (43)
 Synovitis23 (10)21 (11)2 (6)
 Tendon friction rubs8 (4)6 (3)2 (6)
 Proximal muscular weakness14 (6)13 (7)1 (3)
 Pulmonary crackles64 (29)57 (30)7 (20)
 Renal crisis10 (5)10 (5)0 (0)
Autoantibodies, N (%)
 ANA positivity209 (93)177 (93)32 (91)
 Anti-Scl-70 positivity‡50 (26)43 (27)7 (21)
 Anti-centromere positivity‡77 (40)62 (38)15 (48)
Cardiopulmonary investigations
 Vital capacity % of predicted, mean (SD)*96 (82–109)94 (21)99 (24)
 DLCO % of predicted, mean (SD)*62 (50–75)62 (18)67 (13)
 UIP according HRCT, N (%)70 (31)57 (30)13 (37)
 NSIP according HRCT, N (%)69 (31)62 (33)7 (21)
 SPAP >35 mm Hg, N (%)43 (19)40 (21)3 (9)
 LVEF, mean (SD)58 (7.1)61 (8)60 (7)
 Pericardial fluid, N (%)10 (4)9 (5)1 (3)
 Arrhythmia, N (%)55 (24)50 (27)5 (15)
 Conduction defect, N (%)21 (9)20 (11)1 (3)
 6-min walk distance, meters, mean (SD)498 (136)490 (142)540 (93)
 CPET; maximum VO2% of predicted, mean (SD)91 (12)87 (25)96 (24)
Immunosuppressive therapy
 Current77 (34)68 (36)9 (26)
 Previous88 (39)72 (38)16 (46)
SHAQ (0–3), median (IQR)†0.6 (0.3–1.1)0.8 (0.3–1.1)0.3 (0–0.6)
SF-36, median (IQR)‡
 Physical Component Summary Scale40.1 (32–49.5)38 (30.1–47.9)48.3 (42.3–53.8)
 Mental Component Summary Scale51.5 (40–56.1)51.3 (39–56.1)54.4 (40.1–56.5)
  • *<5% missing.

  • †<10% missing.

  • ‡<15% missing.

  • ANA, antinuclear antibody; DcSSc, diffuse cutaneous SSc; DLCO, diffusing capacity for carbon monoxide; MRSS, modified Rodnan Skin Score; NSIP, non-specific interstitial pneumonia; SF-36, Short-Form-36; SHAQ, Scleroderma Health Assessment Questionnaire; SPAP, systolic pulmonary arterial pressure; UIP, usual interstitial pneumonia; VO2 max, maximum volume oxygen.